Aethlon Medical Advances Oncology Study to Final Cohort, Expands IP
AEMD sits 47% above its 52-week low of $1.36.
Summary
Aethlon Medical announced its fiscal year-end results and a corporate update, highlighting significant clinical progress. The company has advanced its Australian oncology study into the third and final dosing cohort, with the first participant in Cohort 3 already treated. This is a key milestone for the clinical-stage biotech, moving it closer to generating pivotal data. Additionally, Aethlon expanded its intellectual property portfolio with new patents for coronavirus-related conditions. While the press release did not include specific financial figures, the clinical and IP advancements are positive developments for the company.
At the time of this announcement, AEMD was trading at $2.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.2M. The 52-week trading range was $1.36 to $27.40. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: PR Newswire.